These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 30130985)

  • 1. Factors associated with physicians' decision to discontinue or down-titrate sulfonylureas for type 2 diabetes patients.
    Laires P; Kurtyka K; Witt EA; Qiu Y; Yu S; Iglay K
    Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):71-79. PubMed ID: 30130985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of hypoglycemic events and HbA1c level on sulfonylurea discontinuation and down-titration.
    Laires PA; Tang J; Fan CP; Li Z; Qiu Y; Iglay K
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):213-220. PubMed ID: 27345181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoglycemia in type 2 diabetes: understanding patients' and physicians' knowledge and experience.
    Fisher SJ; Huang X; Pawaskar M; Witt EA; Rajpathak S; Shankar RR; Inzucchi SE
    Endocrine; 2018 Jun; 60(3):435-444. PubMed ID: 29460218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient and prescriber characteristics among patients with type 2 diabetes mellitus continuing or discontinuing sulfonylureas following insulin initiation: data from a large commercial database.
    Beachler DC; Fernandes G; Deshpande G; Jemison J; Lyons JG; Lanes S; Liu J; McNeill A
    Curr Med Res Opin; 2018 Jun; 34(6):1061-1069. PubMed ID: 29264933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors associated with treatment discontinuation and down-titration in type 2 diabetes patients treated with sulfonylureas.
    Iglay K; Qiu Y; Steve Fan CP; Li Z; Tang J; Laires P
    Curr Med Res Opin; 2016 Sep; 32(9):1567-75. PubMed ID: 27175740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Measures to meet the side effects of sulfonylurea (SU) in the treatment of type 2 diabetes].
    Furukawa H; Ishida H
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():357-61. PubMed ID: 12387018
    [No Abstract]   [Full Text] [Related]  

  • 7. Exploring the Distribution of Prescription for Sulfonylureas in Patients with Type 2 Diabetes According to Cardiovascular Risk Factors Within a Canadian Primary Care Setting.
    Farahani P; Khan S; Oatway M; Dziarmaga A
    J Popul Ther Clin Pharmacol; 2015; 22(3):e228-36. PubMed ID: 26567749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.
    Bron M; Marynchenko M; Yang H; Yu AP; Wu EQ
    Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study.
    Aravind SR; Ismail SB; Balamurugan R; Gupta JB; Wadhwa T; Loh SM; Suryawanshi S; Davies MJ; Girman CJ; Katzeff HL; Radican L; Engel SS; Wolthers T
    Curr Med Res Opin; 2012 Aug; 28(8):1289-96. PubMed ID: 22738801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare resource use and associated costs of hypoglycemia in patients with type 2 diabetes prescribed sulfonylureas.
    Alemayehu B; Liu J; Rajpathak S; Engel SS
    J Diabetes Complications; 2017 Nov; 31(11):1620-1623. PubMed ID: 28844830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HYPOGLYCEMIA INDUCED BY ANTIDIABETIC SULFONYLUREAS.
    Confederat L; Constantin S; Lupaşcu F; Pânzariu A; Hăncianu M; Profire L
    Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):579-84. PubMed ID: 26204670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas.
    Sato R; Watanabe H; Genma R; Takeuchi M; Maekawa M; Nakamura H
    Pharmacogenomics; 2010 Dec; 11(12):1743-50. PubMed ID: 21142918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.
    Ragia G; Petridis I; Tavridou A; Christakidis D; Manolopoulos VG
    Pharmacogenomics; 2009 Nov; 10(11):1781-7. PubMed ID: 19891554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of severe hypoglycemic events from amiodarone-sulfonylureas interactions: A population-based nested case-control study.
    Lai JH; Wang MT; Wu CC; Huang YL; Lu CH; Liou JT
    Pharmacoepidemiol Drug Saf; 2020 Aug; 29(8):842-853. PubMed ID: 32483856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy.
    Bell DS
    Clin Ther; 2004 Nov; 26(11):1714-27. PubMed ID: 15639686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
    Göke R; Gruenberger JB; Bader G; Dworak M
    Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving management of type 2 diabetes mellitus: 3. Sulfonylureas.
    Samraj GP; Quillen DM; Kuritzky L
    Hosp Pract (1995); 1999 Nov; 34(12):129-34, 137, 140. PubMed ID: 10616550
    [No Abstract]   [Full Text] [Related]  

  • 18. Higher risk of sulfonylurea-associated hypoglycemic symptoms in women with type 2 diabetes mellitus.
    Kajiwara A; Kita A; Saruwatari J; Oniki K; Morita K; Yamamura M; Murase M; Koda H; Hirota S; Ishizuka T; Nakagawa K
    Clin Drug Investig; 2015 Sep; 35(9):593-600. PubMed ID: 26293520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulfonylurea monotherapy and emergency room utilization among elderly patients with type 2 diabetes.
    Rajpathak SN; Fu C; Brodovicz K; Engel SS; Heaton PC
    Diabetes Res Clin Pract; 2015 Sep; 109(3):507-12. PubMed ID: 26123984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoglycemic side effects of sulfonylureas and repaglinide in ageing patients - knowledge and self-management.
    Harsch IA; Kaestner RH; Konturek PC
    J Physiol Pharmacol; 2018 Aug; 69(4):. PubMed ID: 30552308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.